Multiple sclerosis (MS) is considered an autoimmune disease associated with immune activity directed against central nervous system antigens. Based on this concept, immunosuppression and immunomodualtion have been the mainstays of therapeutic strategies in MS. During the last decade new therapies have ...
Statin Treatment in Multiple Sclerosis: A Systematic Review and Meta-Analysis Background Multiple sclerosis (MS) is a chronic inflammatory disease that leads to progressive disability. Statins [hydroxymethylglutaryl- CoA (HMG- CoA ... G Pihl-Jensen,A Tsakiri,JL Frederiksen - 《Cns Drugs》 被引...
In a multicenter, randomized, double-blind, placebo-controlled clinical trial, Torkildsen et al investigate whether ω-3 fatty acids reduce magnetic
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the diseas...
Improvement of spasticity with dantrolene sodium in multiple sclerosis has been reliably reported to range from 30% to 40%.1 The results reported by Tolosa et al are in the same "ball park." The complexity of the mechanism of this disease is well known. Attainment of such results in 30% ...
Interferon-β is a current treatment for multiple sclerosis (MS). Interferon-β is thought to exert its therapeutic effects on MS by down-modulating the immune response by multiple potential pathways. Here, we document that treatment of MS patients with interferon β-1a (Rebif) results in a si...
Introduction: Multiple sclerosis (MS) is a chronic and progressive inflammatory disease of the central nervous system. It is most frequently found in women aged between 20 and 40. In Brazil, there are about 35,000 people with MS; the... RA Parizotto,ACM Marese,LS Pivato,... 被引量: 0...
Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-β, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in...
et al. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics J 17, 312–318 (2017). https://doi.org/10.1038/tpj.2016.20 Download citation Received31 July 2015 Revised04 November 2015 Accepted12 February 2016 Published22 March 2016 ...
MULTIPLE SCLEROSIS - THE GUIDE TO TREATMENT AND MANAGEMENT British Journal of Occupational TherapyJewell, Carol B